Pfizer, Spanning the Globe to Defend Lipitor Patents

Emerging markets may be essential to the growth of the global drug industry, but that doesn’t mean growth comes easily in the developing world. It’s become pretty common for countries to fight with drug makers over prices. And patent disputes can crop up anywhere, as generic manufacturers look to get in on the action.

Pfizer has faced both problems in the Philippines this year. The government put price controls on several branded, including Pfizer’s Norvasc and Lipitor, a few months back.

Now, the Financial Times notes, Pfizer is in court there trying to bar the sale of generic Lipitor by United Laboratories, a local drug company. United Laboratories argues that the relevant patent has already expired; Pfizer argues that more recent patents still protect the drug from generic competition.

Under a deal Pfizer reached last year with Indian generics manufacturer Ranbaxy, Lipitor is expected to face generic competition in late 2011.

Map detail via CIA World Factbook

Go to Source

People who read this also read

• Lipitor & the Era of Mega-Blockbusters. (Also: Fungi.)
  Two years from today, if everything goes according to plan, Lipitor will go generic. That’s likely to be the end of an era when big drug makers built their businesses around mega-blockbuster drugs that treat common, chronic conditions. In its magazine section this weekend, the Financial Times...
• Teva Outwrestles Pfizer to Land Generics Maker Ratiopharm
  The world’s biggest generic drug maker is getting bigger with the announcement this morning that Israel’s Teva Pharmaceutical had won the bidding against Pfizer for Germany’s Ratiopharm Group. The pricetag: $4.97 billlion. A bidding contest had been dragging on for months for Ratio...
• Pfizer, Like Much of Big Pharma, Pushes Further Into Generics
  The distance between Big Pharma and the generic drugs business keeps getting narrower. Under a deal with an Indian drugs shop Strides Arcolab, Pfizer will add some 40 off-patent drugs, including many cancer medicines, to the list of products it sells in the U.S. Here’s a statement Pfizer put out des...
• Of Pfizer, a New Treatment for a Rare Disease and Carrot Cells
  Pfizer’s deal today with Israeli biotech Protalix BioTherapeutics to license most of the rights for a promising therapy for a rare disease caught our eye for a number of reasons: The deal gives Pfizer rights to sell a treatment for Gaucher’s disease that will soon go for FDA approval. Pf...
• Medicaid Funding Subject Of Lawsuits In Massachusetts, Idaho
  Some hospitals are suing Massachusetts' Medicaid program for underpaying. Idaho health agencies are broadening their own lawsuit against the state on Medicaid payment rules. Boston Herald: "Six community hospitals will formally file a lawsuit against the state today, ratcheting up a dispu...